Loading
companiesCompany
BioInvent International
BioInvent International is a Sweden-based biotechnology company running 4 late-stage cancer trials of BI-1607, Ipilimumab (YervoyTM and BI-1910 in melanoma, uveal melanoma and non-small-cell lung cancer.
Also called: BioInvent International AB
Overview
BioInvent International, based in Lund, Sweden, is a biotechnology company. BioInvent International is a clinical-stage company that discovers and develops antibodies for cancer immunotherapy, using its proprietary F.I.R.S.T. platform and n-CoDeR antibody library. On ClinicalTrials.gov it is the lead sponsor of 4 recruiting or active phase 2 and phase 3 interventional cancer trials, testing BI-1607, Ipilimumab (YervoyTM, BI-1910, BI1206 and BI-1808 in melanoma, uveal melanoma, non-small-cell lung cancer, hepatocellular carcinoma and ovarian cancer. The largest, NCT04219254 (A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumours), plans to enrol 197 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Similar pages
- TrialA Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors
Shares Uveal melanoma, Hepatocellular carcinoma, Non-small-cell lung cancer.
- TargetGNAQ
Shares Uveal melanoma, Hepatocellular carcinoma, Melanoma, Non-small-cell lung cancer.
- JournalMelanoma research
Shares Uveal melanoma, Melanoma.
- JournalPigment cell & melanoma research
Shares Uveal melanoma, Melanoma.
- TrialA Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
Shares Uveal melanoma, Melanoma.
- Trial(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
Shares Uveal melanoma, Melanoma.
- TrialA Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors
Shares Uveal melanoma, Melanoma.
- CompanyiOnctura
Shares Uveal melanoma, Melanoma, Non-small-cell lung cancer.
cancers
trials
A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid TumorsBI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid TumorsDifferent Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma